EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Influenza Vaccine Effectiveness Against Influenza A(H1N1)pdm09‐Associated Hospitalizations With SARI in Beijing, China, in the 2024–2025 Season

Chunna Ma, Ying Sun iD, Jiaxin Ma, Yingying Wang, Xiaodi Hu, Ying Shen, Li Zhang, Jiaojiao Zhang, Lu Zhang, Wei Duan, Jia Li, Quanyi Wang und 2 weitere

Influenza and Other Respiratory Viruses · 2026

DOI: 10.1111/irv.70248 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Influenza and Other Respiratory Viruses, 2026. Verfasst von Chunna Ma und 13 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Research Center for Respiratory Infectious Diseases, Beijing, China. Hauptthemen laut MEDLINE: Influenza A Virus, H1N1 Subtype, Influenza, Human, Influenza Vaccines, Hospitalization. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Natural Science Foundation, Capital's Funds for Health Improvement and Research, High Level Public Health Technical Talent Training Plan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In the 2024–2025 season, influenza activity returned to pre‐COVID‐19 pandemic levels, with A(H1N1)pdm09 as the predominant subtype. Reassessment vaccine effectiveness (VE) in hospitalized patients is critical to inform potential adjustments to vaccination policy.

Methods

Using a test‐negative design, we evaluated the VE of the seasonal influenza vaccine during the 2024–2025 season against A(H1N1)pdm09‐associated hospitalizations with severe acute respiratory infections (SARI) in Beijing, China, from December 9, 2024 to February 9, 2025. VE was estimated by comparing the odds of influenza vaccination between case‐patients (those testing positive for A(H1N1)pdm09) and controls (influenza test‐negative patients), applying inverse‐propensity‐to‐be‐vaccinated weights.

Results

The analysis included 1608 hospitalized SARI patients (17.4% tested positive for A(H1N1)pdm09; 13.8% were vaccinated overall). The adjusted VE against A(H1N1)pdm09‐associated hospitalizations was 18.8% (95% CI: 0.9% to 33.6%) overall. Specifically, the VE was 45.4% (95% CI: 10.0% to 67.1%) in children aged 0.5–17 years, 43.8% (95% CI: −20.8% to 76.1%) in adults aged 18–59 years, and 8.6% (95% CI: −15.8% to 27.9%) in older adults ≥ 60 years. Among individuals with chronic conditions, the VE was 18.5% (95% CI: −2.3% to 35.2%) and was higher among those with chronic respiratory conditions (40.6%, 95% CI: −1.7% to 65.7%).

Conclusions

During the 2024–2025 season in Beijing, the overall VE against A(H1N1)pdm09‐associated SARI hospitalizations was suboptimal. However, moderate VE was observed among children and younger adults, while limited effectiveness was seen in the elderly. Optimizing influenza vaccination strategies, including the introduction of high‐dose or adjuvanted vaccines to enhance immune response in older adults, is crucial to alleviate influenza‐associated hospitalizations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Influenza A Virus, H1N1 SubtypeInfluenza, HumanInfluenza VaccinesHospitalizationVaccine EfficacyRespiratory Tract InfectionsHumansAdultFemaleMiddle AgedMaleAdolescentChildYoung AdultChild, PreschoolBeijingAgedInfantSeasonsVaccination

Stichwörter der Autor:innen

Chinahospitalizationinfluenzatest‐negative designvaccine effectiveness

Substanzen

Influenza Vaccines

Autor:innen und Institutionen

  • Beijing Research Center for Respiratory Infectious Diseases, Beijing, China.
  • Beijing Key Laboratory of Surveillance, Early Warning and Pathogen Research on Emerging Infectious Diseases, Beijing Center for Disease Prevention and Control, Beijing, China.
  • Institute for Infectious Disease and Endemic Disease Control, Beijing Center for Disease Prevention and Control, Beijing, China.
  • School of Public Health, Capital Medical University, Beijing, China.

ORCID-Profile: Ying Sun

Förderung

  • Beijing Natural Science Foundation
  • Capital's Funds for Health Improvement and Research
  • High Level Public Health Technical Talent Training Plan
  • Beijing Research Center for Respiratory Infectious Diseases Project

Zitieren

APA

Ma, C., Sun, Y., Ma, J., Wang, Y., Hu, X., Shen, Y., Zhang, L., Zhang, J., Zhang, L., Duan, W., Li, J., Wang, Q., Zhang, D., & Yang, P. (2026). Influenza Vaccine Effectiveness Against Influenza A(H1N1)pdm09‐Associated Hospitalizations With SARI in Beijing, China, in the 2024–2025 Season. Influenza and Other Respiratory Viruses. https://doi.org/10.1111/irv.70248

Vancouver

Ma C, Sun Y, Ma J, Wang Y, Hu X, Shen Y, et al. Influenza Vaccine Effectiveness Against Influenza A(H1N1)pdm09‐Associated Hospitalizations With SARI in Beijing, China, in the 2024–2025 Season. Influenza and Other Respiratory Viruses. 2026. doi:10.1111/irv.70248

BibTeX
@article{Ma2026,
  author = {Ma, Chunna and Sun, Ying and Ma, Jiaxin and Wang, Yingying and Hu, Xiaodi and Shen, Ying and Zhang, Li and Zhang, Jiaojiao and Zhang, Lu and Duan, Wei and Li, Jia and Wang, Quanyi and Zhang, Daitao and Yang, Peng},
  title = {Influenza Vaccine Effectiveness Against Influenza A(H1N1)pdm09‐Associated Hospitalizations With SARI in Beijing, China, in the 2024–2025 Season},
  journal = {Influenza and Other Respiratory Viruses},
  year = {2026},
  doi = {10.1111/irv.70248}
}
Kostenlos starten →